Navigation Links
Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
Date:8/14/2009

ale quantities over the second quarter 2008. Retail revenues accounting for 20% of total revenues decreased 24% due to weak consumer demand for non-essential drugs.

Gross margins for the second quarter of 2009 increased to 57.9% as compared to 50.0% in the second quarter of 2008. Dr. Zhongyi Liu, Chairman and CEO of Lotus commented, "We are very pleased with our growth in sales quantities and gross margins of this quarter. Our pricing policy for 2009 has been adjusted accordingly due to the expected inflation contraction on the wholesale level nationally. We have been able to reduce the cost of sales mainly because Active Pharmaceutical Ingredient ("API") and essential medicine prices have dropped since the onset of economic slowdown."

Total operating expenses for the second quarter 2009 were $2.6 million, a 63% decrease from the second quarter of 2008. The decrease resulted from the decrease of selling expenses in relation to our drugs that have established certain market shares, which was due to the profit margins we have given away to our agents who in turn are incentivized to sell our established drugs at competitive prices.

Dr. Liu commented, "We are very pleased to obtain the approval from the Beijing Land Planning Bureau for permitting us to build a new office building on our current production base which was previously industrial-use-only land in Beijing. This means that we can finally bring all of our operational units such as administration, sales, R&D and production into a single office building. This is another important step we made towards improving our operational efficiency."

Net income for the second quarter of 2009 was $4.8 million, or $0.10 per diluted share, compared to $2.2 million, or $0.05 per diluted share, in the second quarter of 2008.

The Company's cash position at the end of the second quarter was $1.8 million, compared to $1.3 million at the
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets
2. Lotus Scarless Hair Transplantation (International) Medical Chain Institute Opens New Center on Beijings Prestigious ChangAn Avenue
3. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
4. NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
5. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
6. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
7. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
8. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
10. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
11. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 DuPont Pioneer and ... more than double the acreage contracted for Plenish® ... its soybean crush facility in Salisbury, Md. The ... will target several markets including foodservice and food ... performance. , For the 2015 growing season, Perdue ...
(Date:10/25/2014)... (PRWEB) October 24, 2014 Today, Nerium ... announced the winners of its “Reflect Your Youth” contest, ... not only seen a difference in their skin since ... a new outlook on life as a result of ... originated as an effort by Nerium International to inspire ...
(Date:10/25/2014)... Great Barrington, MA (PRWEB) October 25, 2014 ... contamination control products, is pleased to announce the ... to achieve the highest level of contamination containment ... in ISO Class 3 and higher cleanroom environments, ... continuous filament polyester knit laundered wiper that continues ...
(Date:10/25/2014)... , Oct. 24, 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: ... presented at the Fourth International Symposium on Thymosins in ... Italy.  "When thymosin beta 4 (TB4) ... into the peritoneal cavity in a rodent model of ... throughout the brain parenchyma (the functional tissue of the ...
Breaking Biology Technology:DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2
... article, the City of Milwaukee has negotiated a three-year "franchise-like" ... company to start an Internet protocol video service to compete ... will be considered by the Milwaukee Common Council, AT&T would ... by the service. , , While there are ...
... big business (untold billions of dollars every year), they also ... of the fundamental ethical principle of informed consent ... is that conducting a clinical trial carries with it the ... positive or negative or even if the clinical trial is ...
... For the second time this year, a tech-based company in ... to the public. Called an initial public offering, this kind ... and investors who are directly involved, but to others who ... Madison-based biotechnology company, has filed papers with the Securities ...
Cached Biology Technology:State video franchises vs. universal service: Grasping the total picture 2State video franchises vs. universal service: Grasping the total picture 3State video franchises vs. universal service: Grasping the total picture 4What patients want: A story of choice, clinical trials & evidence-based medicine 2What patients want: A story of choice, clinical trials & evidence-based medicine 3What patients want: A story of choice, clinical trials & evidence-based medicine 4What patients want: A story of choice, clinical trials & evidence-based medicine 5Wisconsin IPOs are a harbinger of growing tech economy 2Wisconsin IPOs are a harbinger of growing tech economy 3
(Date:10/22/2014)... The Nano-Bio Manufacturing Consortium (NBMC), an industry-academia ... (AFRL), has chosen a project proposed by the Arizona ... Arizona College of Medicine – Tucson ... is to assess different sweat collection methods and devices ... under a variety of human-body conditions, the results of ...
(Date:10/19/2014)... access in India over the last 30 years ... emissions growth during that time, according to a ... Climate Change ., "Energy access is fundamental to ... life, including education, communication, and health," says IIASA ... While increased energy access is widely agreed to ...
(Date:10/18/2014)... undiagnosed, suspected genetic conditions, a certain type of exome ... yield than traditional molecular diagnostic methods, according to a ... being released to coincide with the American Society of ... the protein­coding region of the genome (the complete set ... or organism), has been rapidly applied in research settings ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Improved electricity access has little impact on climate change 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
... The next time you are stung by a ... venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs ... or diagnose cancer. This research, described in the August ... ( http://www.fasebj.org ), shows how modified melittin may revolutionize ...
... by which Helicobacter pylori , the only known cancer-causing ... The new study, in the journal Oncogene , reports ... pylori infection and stomach cancer, the second leading cause ... population is infected with H. pylori, a bacterium that can ...
... genomes that potentially hide a rich array of pharmaceutical ... antibiotic. The study, reported in the August issue of ... serious diseases that are rapidly acquiring multi-drug resistance. ... successfully used a ,genome mining, approach to find and ...
Cached Biology News:Cancer-causing bacterium targets tumor-suppressor protein 2Cancer-causing bacterium targets tumor-suppressor protein 3Mining bacterial genomes reveals valuable 'hidden' drugs 2
Ets-1...
Request Info...
Secure-Seal™ spacer, one well, 20 mm diameter, 0.12 mm deep *set of 100*...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: